Literature DB >> 25851069

Increased Prevalence and Resistance of Important Pathogens Recovered from Respiratory Specimens of Cystic Fibrosis Patients During a Decade.

Lena Raidt1, Evgeny A Idelevich, Angelika Dübbers, Peter Küster, Pavel Drevinek, Georg Peters, Barbara C Kahl.   

Abstract

BACKGROUND: The study objective was to identify changes of prevalence and resistance of important pathogens in specimens of cystic fibrosis (CF) patients within a decade.
METHODS: Samples of 94 patients, who attended 2 CF centers from 2001 to 2011 were retrospectively analyzed.
RESULTS: Staphylococcus aureus was the most prevalent organism (74.5% in 2011) with an increase of methicillin-resistant S. aureus in patients (0% vs. 9.6%, n = 9). Resistance of S. aureus to gentamicin decreased (41.8% vs. 21%; P < 0.001), whereas resistance to rifampicin and trimethoprim/sulfamethoxazole (P < 0.05) increased significantly with a trend to increased resistance to clindamycin and erythromycin (P = 0.063). Methicillin-resistant S. aureus isolates belonged to 6 spa types (t003, t008, t011, t034, t045, t548). There was a significant increase of Pseudomonas aeruginosa prevalence (63.8% in 2011 vs. 46.8% in 2001, P = 0.019). Resistance of P. aeruginosa increased significantly to imipenem, gentamicin, amikacin, tobramycin, ciprofloxacin and fosfomycin, whereas resistance to piperacillin-tazobactam, meropenem and aztreonam decreased. Significantly fewer Stenotrophomonas maltophilia isolates were susceptible to all the analyzed antibiotics (trimethoprim/sulfamethoxazole, ciprofloxacin and colistin) in 2011 compared with 2001 (13.5% vs. 42.1%; P = 0.023), whereas the resistance to colistin increased significantly (11.1% vs. 62.2%; P < 0.001). Burkholderia cepacia complex and nontuberculous mycobacteria were not detected in 2001 but in 2011 in 7.4% (n = 9) and 7.4% (n = 9) of patients, respectively. B. cepacia complex isolates belonged to 8 multilocus sequence types.
CONCLUSIONS: Our retrospective analysis revealed an increase of important CF-related pathogens, the emergence of new pathogens and a substantial increase of multidrug-resistant CF-specific isolates. Our findings are of importance to clinicians for the alertness of local epidemiology, which may be useful for prevention and treatment strategies.

Entities:  

Mesh:

Year:  2015        PMID: 25851069     DOI: 10.1097/INF.0000000000000714

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

1.  Clinical and microbiological profile of chronic Burkholderia cepacia complex infections in a cystic fibrosis reference hospital in Brazil.

Authors:  C P da Costa Capizzani; N C Caçador; L A G M M Torres; L Tonani; P Vandamme; A L da Costa Darini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-24       Impact factor: 3.267

2.  Intra- and Interspecies Effects of Outer Membrane Vesicles from Stenotrophomonas maltophilia on β-Lactam Resistance.

Authors:  Simon Devos; Stephan Stremersch; Koen Raemdonck; Kevin Braeckmans; Bart Devreese
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.

Authors:  Rongpong Plongla; Clair L Preece; John D Perry; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2017-02-22       Impact factor: 5.948

4.  Severe Sepsis in Pediatric Liver Transplant Patients: The Emergence of Multidrug-Resistant Organisms.

Authors:  Alicia M Alcamo; Lauren J Alessi; S Noona Vehovic; Neha Bansal; Geoffrey J Bond; Joseph A Carcillo; Michael Green; Marian G Michaels; Rajesh K Aneja
Journal:  Pediatr Crit Care Med       Date:  2019-07       Impact factor: 3.624

5.  Interference with Pseudomonas aeruginosa Quorum Sensing and Virulence by the Mycobacterial Pseudomonas Quinolone Signal Dioxygenase AqdC in Combination with the N-Acylhomoserine Lactone Lactonase QsdA.

Authors:  Franziska S Birmes; Ruth Säring; Miriam C Hauke; Niklas H Ritzmann; Steffen L Drees; Jens Daniel; Janina Treffon; Eva Liebau; Barbara C Kahl; Susanne Fetzner
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

6.  Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis.

Authors:  Ian Eltringham; Julie Pickering; Helen Gough; Clair L Preece; John D Perry
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

7.  Strong incidence of Pseudomonas aeruginosa on bacterial rrs and ITS genetic structures of cystic fibrosis sputa.

Authors:  Laurence Pages-Monteiro; Romain Marti; Carine Commun; Nolwenn Alliot; Claire Bardel; Helene Meugnier; Michele Perouse-de-Montclos; Philippe Reix; Isabelle Durieu; Stephane Durupt; Francois Vandenesch; Jean Freney; Benoit Cournoyer; Anne Doleans-Jordheim
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

8.  Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.

Authors:  Alaya Mikalauskas; Michael D Parkins; Keith Poole
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

Review 9.  Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes.

Authors:  Réka Bodnár; Ágnes Mészáros; Máté Oláh; Tamás Ágh
Journal:  Patient Prefer Adherence       Date:  2016-02-16       Impact factor: 2.711

10.  Clonal Diversity, Biofilm Formation, and Antimicrobial Resistance among Stenotrophomonas maltophilia Strains from Cystic Fibrosis and Non-Cystic Fibrosis Patients.

Authors:  Arianna Pompilio; Vincenzo Savini; Ersilia Fiscarelli; Giovanni Gherardi; Giovanni Di Bonaventura
Journal:  Antibiotics (Basel)       Date:  2020-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.